Jubilant Ingrevia Ltd.

“Jubilant Ingrevia is a commodity-to-specialty transition story that has failed to deliver: ROCE has collapsed from 29% to 11%, debt has tripled to fund a CDMO pivot against entrenched competitors, revenue has declined 14% from peak, and promoters have sold 6% of their stake during the downturn. At 38x trailing earnings with no margin of safety, the stock is priced for a transformation that management has not executed in three years of trying. Every segment of analysis — business quality, moat durability, financial health, management competence, and valuation — returned a negative signal. This is not a business worth owning at any price near current levels.”